<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570865</url>
  </required_header>
  <id_info>
    <org_study_id>DAPA-MEMS</org_study_id>
    <nct_id>NCT04570865</nct_id>
  </id_info>
  <brief_title>Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®</brief_title>
  <acronym>DAPA-MEMS</acronym>
  <official_title>Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV)&#xD;
      patients with or without diabetes who have CardioMEMS® implanted to assess the impact on&#xD;
      pulmonary artery pressure measurements after 12 weeks of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior studies have demonstrated an association between the use of sodium-glucose&#xD;
      cotransporter 2 (SGLT-2) inhibitors for diabetic patients and reductions in composite primary&#xD;
      outcomes of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke, as&#xD;
      well as reductions in heart failure among patients with diabetes. The 2019 DAPA-HF trial&#xD;
      studied whether the addition of the SCLT-2 inhibitor dapagliglozin could benefit patients&#xD;
      with heart failure with reduced ejection fraction (HFrEF), either with or without diabetes.&#xD;
      Results indicated that that SGLT-2 inhibitors resulted in 4.9% absolute reduction in the&#xD;
      cardiovascular death or worsening heart failure and a 2.3% absolute reduction in all-cause&#xD;
      mortality in patients with and without diabetes. Dapagliflozin is FDA approved to reduce the&#xD;
      risk of cardiovascular death or hospitalization in patients with HFrEF with or without Type 2&#xD;
      diabtes. The mechanisms of cardiovascular benefit remain unclear, however it is likely to be&#xD;
      driven by a reduction in heart failure death given that rates of myocardial infarction were&#xD;
      similar between treatment arms.&#xD;
&#xD;
      The CardioMEMS® system is an implantable device that can measure pulmonary artery systolic,&#xD;
      diastolic and mean pressure on a daily basis. It has been shown convincingly that monitoring&#xD;
      the MEMS device results in reduced pulmonary pressures and in turn a reduction in heart&#xD;
      failure hospitalizations.&#xD;
&#xD;
      The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV)&#xD;
      patients with or without diabetes who have CardioMEMS® implanted to assess the impact on&#xD;
      pulmonary artery pressure measurements after 12 weeks of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Dapagliflozin on pulmonary diastolic pressure from baseline to 12 weeks of therapy Secondary End Points</measure>
    <time_frame>12 weeka</time_frame>
    <description>PA diastolic pressure change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the change in PA pressures, systolic and mean, from baseline to 12 weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>PA pressure changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the change in NT-ProBNP from baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>NTproBNP change</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compare total diuretic dose from baseline to 12 weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>diuretic dose</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine the change in 6 min walk distance from baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>6 MWT</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare the change in KCCQ from baseline to 12 weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>KCCQ</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in renal function estimated GFR from baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>renal function</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in weight baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>weight</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>Dapagliglozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.</description>
    <arm_group_label>Dapagliglozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioMEMS</intervention_name>
    <description>The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.</description>
    <arm_group_label>Dapagliglozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Diagnosis of HFrEF and existing CardioMEMs in place&#xD;
&#xD;
          2. Patients who have historically been compliant with CardioMEMS followup&#xD;
&#xD;
          3. Ejection fraction &lt; or = to 40%&#xD;
&#xD;
          4. New York Heart Association (NYHA) class II-IV heart failure&#xD;
&#xD;
          5. Able to read and write in English Exclusion Criteria&#xD;
&#xD;
        1. creatinine clearance less than or equal to 45 2. History of renal transplant 3. systolic&#xD;
        blood pressure less than 85 on time of initiation of drug 4. intolerance/allergy to farxiga&#xD;
        5. pregnant patients or those who are planning to become pregnant during the study period&#xD;
        6. unable to read and write in English 7. acutely hospitalized patients or those who were&#xD;
        hospitalized in the past 30 days 8. history of noncompliance with CardioMEMS followup 9.&#xD;
        History of frequent mycotic urinary tract infections 10. History of organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James T Heywood, MD</last_name>
      <phone>858-824-5073</phone>
      <email>heywood.james@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Melody Hermel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samantha Bagsic, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Kuo, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925 2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389 4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303 5. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet. 2011;377(9766):658-666. doi:10.1016/S0140-6736(11)60101-3</citation>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>James Thomas Heywood</investigator_full_name>
    <investigator_title>Director of the Advanced Heart Failure Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

